PAP
KTTA icon

Persistent Asset Partners’s Pasithea Therapeutics KTTA Stock Holding History

Persistent Asset Partners’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Hold
290,555
– – 0.08% 188
2025
Q4 		$375K Buy
+290,555
New +$255K 0.17% 158

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Persistent Asset Partners's KTTA Position: Q1 2026 in Review

Persistent Asset Partners held its Pasithea Therapeutics (KTTA) position steady in Q1 2026 at 290,555 shares worth $216K. The position accounts for 0.08% of the portfolio, ranked #188.

Persistent Asset Partners first reported a position in KTTA in Q4 2025 and has held it in 2 quarters since. The position peaked at $375K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Persistent Asset Partners held 290,555 shares of Pasithea Therapeutics worth $216K as of Q1 2026.
  • Persistent Asset Partners left its Pasithea Therapeutics share count unchanged in Q1 2026.
  • Pasithea Therapeutics made up 0.08% of Persistent Asset Partners's portfolio in Q1 2026, its #188 holding.
  • Persistent Asset Partners first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Pasithea Therapeutics position peaked at $375K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.